{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T12:29:02Z","timestamp":1744892942073,"version":"3.37.3"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1124\/jpet.122.001558","type":"journal-article","created":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T15:10:17Z","timestamp":1688137817000},"page":"55-65","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["A Mathematical Model to Investigate the Effects of Ceralasertib and Olaparib in Targeting the Cellular DNA Damage Response Pathway"],"prefix":"10.1016","volume":"387","author":[{"given":"Kira","family":"Pugh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Davies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8372-7349","authenticated-orcid":false,"given":"Gibin","family":"Powathil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.122.001558_bib1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41467-018-07729-2","article-title":"ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken replication forks","volume":"10","author":"Balmus","year":"2019","journal-title":"Nat Commun"},{"key":"10.1124\/jpet.122.001558_bib2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-1-4939-0888-2_2","article-title":"Cell cycle regulation by checkpoints","volume":"1170","author":"Barnum","year":"2014","journal-title":"Methods Mol Biol"},{"key":"10.1124\/jpet.122.001558_bib3","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.3390\/biom5031912","article-title":"Targeting the Checkpoint to Kill Cancer Cells","volume":"5","author":"Benada","year":"2015","journal-title":"Biomolecules"},{"key":"10.1124\/jpet.122.001558_bib4","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1158\/2159-8290.CD-16-0860","article-title":"Targeting DNA Repair in Cancer: Beyond PARP Inhibitors","volume":"7","author":"Brown","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1124\/jpet.122.001558_bib5","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ctrv.2017.08.013","article-title":"DNA damage response inhibitors: Mechanisms and potential applications in cancer therapy","volume":"60","author":"Carrassa","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1124\/jpet.122.001558_bib6","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrm.2017.48","article-title":"Non-homologous DNA end joining and alternative pathways to double-strand break repair","volume":"18","author":"Chang","year":"2017","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1124\/jpet.122.001558_bib7","doi-asserted-by":"crossref","first-page":"13545","DOI":"10.1038\/srep13545","article-title":"Bridging the gap between in vitro and in vivo: Dose and schedule predictions for the ATR inhibitor AZD6738","volume":"5","author":"Checkley","year":"2015","journal-title":"Sci Rep"},{"key":"10.1124\/jpet.122.001558_bib8","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1096\/fj.02-0752rev","article-title":"Oxidative DNA damage: mechanisms, mutation, and disease","volume":"17","author":"Cooke","year":"2003","journal-title":"FASEB J"},{"key":"10.1124\/jpet.122.001558_bib9","first-page":"130","article-title":"DNA double strand break repair via non-homologous end-joining","volume":"2","author":"Davis","year":"2013","journal-title":"Transl Cancer Res"},{"key":"10.1124\/jpet.122.001558_bib10","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/mutage\/geh025","article-title":"Endogenous DNA damage in humans: a review of quantitative data","volume":"19","author":"De Bont","year":"2004","journal-title":"Mutagenesis"},{"key":"10.1124\/jpet.122.001558_bib11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4161\/cc.7.1.5149","article-title":"Importance of the cell cycle phase for the choice of the appropriate DSB repair pathway, for genome stability maintenance: the trans-S double-strand break repair model","volume":"7","author":"Delac\u00f4te","year":"2008","journal-title":"Cell Cycle"},{"key":"10.1124\/jpet.122.001558_bib12","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13045-017-0443-x","article-title":"The cell cycle checkpoint inhibitors in the treatment of leukemias","volume":"10","author":"Ghelli Luserna di Rora\u2019","year":"2017","journal-title":"J Hematol Oncol"},{"key":"10.1124\/jpet.122.001558_bib13","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0031-6997(25)06847-4","article-title":"The search for synergy: a critical review from a response surface perspective","volume":"47","author":"Greco","year":"1995","journal-title":"Pharmacol Rev"},{"key":"10.1124\/jpet.122.001558_bib14","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/emboj.2008.15","article-title":"DNA-damage repair; the good, the bad, and the ugly","volume":"27","author":"Hakem","year":"2008","journal-title":"EMBO J"},{"key":"10.1124\/jpet.122.001558_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.18.00068","article-title":"Blackboard to Bedside: A Mathematical Modeling Bottom-Up Approach Toward Personalized Cancer Treatments","volume":"3","author":"Hamis","year":"2019","journal-title":"JCO Clin Cancer Inform"},{"key":"10.1124\/jpet.122.001558_bib16","series-title":"The Physics of Cancer: Research Advances","first-page":"1","article-title":"Uncertainty and Sensitivity Analyses Methods for Agent-Based Mathematical Models: An Introductory Review","author":"Hamis","year":"2020"},{"key":"10.1124\/jpet.122.001558_bib17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11538-021-00935-y","article-title":"Targeting Cellular DNA Damage Responses in Cancer: An In Vitro-Calibrated Agent-Based Model Simulating Monolayer and Spheroid Treatment Responses to ATR-Inhibiting Drugs","volume":"83","author":"Hamis","year":"2021","journal-title":"Bull Math Biol"},{"key":"10.1124\/jpet.122.001558_bib18","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.molonc.2011.07.001","article-title":"The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings","volume":"5","author":"Helleday","year":"2011","journal-title":"Mol Oncol"},{"key":"10.1124\/jpet.122.001558_bib19","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/cas.12366","article-title":"Targeting DNA damage response in cancer therapy","volume":"105","author":"Hosoya","year":"2014","journal-title":"Cancer Sci"},{"key":"10.1124\/jpet.122.001558_bib20","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1186\/s12885-021-08800-w","article-title":"Combined effects of cigarette smoking, DNA methyltransferase 3B genetic polymorphism, and DNA damage on lung cancer","volume":"21","author":"Huang","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1124\/jpet.122.001558_bib21","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a012740","article-title":"Repair of strand breaks by homologous recombination","volume":"5","author":"Jasin","year":"2013","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1124\/jpet.122.001558_bib22","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1158\/1535-7163.MCT-13-0906-T","article-title":"New insights into PARP inhibitors\u2019 effect on cell cycle and homology-directed DNA damage repair","volume":"13","author":"Jelinic","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"10.1124\/jpet.122.001558_bib23","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1038\/onc.2014.276","article-title":"ATR inhibition preferentially targets homologous recombination-deficient tumor cells","volume":"34","author":"Krajewska","year":"2015","journal-title":"Oncogene"},{"key":"10.1124\/jpet.122.001558_bib24","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1038\/s41388-020-1328-y","article-title":"Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells","volume":"39","author":"Lloyd","year":"2020","journal-title":"Oncogene"},{"key":"10.1124\/jpet.122.001558_bib25","doi-asserted-by":"crossref","first-page":"E42","DOI":"10.1208\/ps040442","article-title":"Pharmacodynamic modeling of chemotherapeutic effects: application of a transit compartment model to characterize methotrexate effects in vitro","volume":"4","author":"Lobo","year":"2002","journal-title":"AAPS PharmSci"},{"key":"10.1124\/jpet.122.001558_bib26","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3389\/fphar.2016.00421","article-title":"Pharmacodynamic modeling of cell cycle effects for gemcitabine and trabectedin combinations in pancreatic cancer cells","volume":"7","author":"Miao","year":"2016","journal-title":"Front Pharmacol"},{"key":"10.1124\/jpet.122.001558_bib27","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00280-015-2907-4","article-title":"Pharmacodynamic modeling of combined chemotherapeutic effects predicts synergistic activity of gemcitabine and trabectedin in pancreatic cancer cells","volume":"77","author":"Miao","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/jpet.122.001558_bib28","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1158\/1535-7163.MCT-16-0378","article-title":"AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells","volume":"16","author":"Min","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"10.1124\/jpet.122.001558_bib29","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res"},{"key":"10.1124\/jpet.122.001558_bib30","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.molcel.2015.10.040","article-title":"Targeting the DNA Damage Response in Cancer","volume":"60","author":"O\u2019Connor","year":"2015","journal-title":"Mol Cell"},{"key":"10.1124\/jpet.122.001558_bib31","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nrg.2017.47","article-title":"Synthetic lethality and cancer","volume":"18","author":"O\u2019Neil","year":"2017","journal-title":"Nat Rev Genet"},{"key":"10.1124\/jpet.122.001558_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jtbi.2012.05.015","article-title":"Modelling the effects of cell-cycle heterogeneity on the response of a solid tumour to chemotherapy: biological insights from a hybrid multiscale cellular automaton model","volume":"308","author":"Powathil","year":"2012","journal-title":"J Theor Biol"},{"key":"10.1124\/jpet.122.001558_bib33","doi-asserted-by":"crossref","first-page":"4959","DOI":"10.1093\/nar\/gkg703","article-title":"Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination","volume":"31","author":"Schultz","year":"2003","journal-title":"Nucleic Acids Res"},{"key":"10.1124\/jpet.122.001558_bib34","first-page":"51","article-title":"Analyzing the G2\/M checkpoint","volume":"280","author":"Stark","year":"2004","journal-title":"Methods Mol Biol"},{"key":"10.1124\/jpet.122.001558_bib35","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.cell.2017.01.002","article-title":"Endogenous DNA Damage as a Source of Genomic Instability in Cancer","volume":"168","author":"Tubbs","year":"2017","journal-title":"Cell"},{"key":"10.1124\/jpet.122.001558_bib36","doi-asserted-by":"crossref","first-page":"44289","DOI":"10.18632\/oncotarget.6247","article-title":"The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo","volume":"6","author":"Vendetti","year":"2015","journal-title":"Oncotarget"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524170929?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524170929?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.122.001558","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T13:31:01Z","timestamp":1739971861000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524170929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S0022356524170929"],"URL":"https:\/\/doi.org\/10.1124\/jpet.122.001558","relation":{},"ISSN":["0022-3565"],"issn-type":[{"type":"print","value":"0022-3565"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Mathematical Model to Investigate the Effects of Ceralasertib and Olaparib in Targeting the Cellular DNA Damage Response Pathway","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.122.001558","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}